60
Participants
Start Date
December 27, 2021
Primary Completion Date
December 30, 2024
Study Completion Date
December 30, 2024
QLETLI
80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
Peking Union Medical College Hospital, Beijing
The Second Xiangya Hospital of Central South University, Changsha
The First Affiliated Hospital of Chongqing Medical University, Chongqing
The second hospital of Jilin University, Jilin
Tianjin Medical University Eye Hospital, Tianjin
Renmin Hospital of Wuhan University, Wuhan
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Lead Sponsor
Bio-Thera Solutions
INDUSTRY